Howard Liang
CFO and Chief Strategy Officer
Pharmaceuticals
BeiGene
China
Biography
· Former Managing Director and Head of Biotechnology Equity Research at Leerink Partners · Institutional Investor All-America Research Team, Biotechnology / Mid- & Small-Cap, 2015; Bloomberg Markets Top US Analysts in Biotechnology, 2012; Wall Street Journal “Best of the Street” in Biotechnology and Pharmaceuticals, 2010 and in Biotechnology, 2008 · Senior biotechnology analyst at AG Edwards, JMP Securities; Associate Analyst at Prudential Securities covering major and specialty pharmaceuticals · Senior Scientist at Abbott Laboratories and member of industry’s leading structure-based drug design teams; authored review and 13 papers including six in Nature, Science, and Proceedings of National Academy of Sciences · M.B.A., and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago · B.S. in Chemistry from Peking University
Research Interest
Biochemistry, Toxicology, Pharmacology
